Print Page     Close Window     

SEC Filings

S-3
SERES THERAPEUTICS, INC. filed this Form S-3 on 03/16/2017
Entire Document
 


Section 10.2. Notices.

Any notice or communication by the Company or the Trustee to the other, or by a Holder to the Company or the Trustee, is duly given if in writing and delivered in person or mailed by first-class mail (registered or certified, return receipt requested), facsimile transmission, email or overnight air courier guaranteeing next day delivery, to the others’ address:

if to the Company:

Seres Therapeutics, Inc.

200 Sidney Street

Cambridge, Massachusetts 02139

Attention: Thomas DesRosier, Chief Legal Officer

Telephone: 617-945-9626

with a copy to:

Latham & Watkins LLP

200 Clarendon Street, 27th Floor

Boston, Massachusetts 02116

Attention: Peter N. Handrinos

Telephone: 617-948-6000

if to the Trustee:

Wilmington Trust, N.A.

Global Capital Markets

50 South Sixth Street, Suite 1290

Minneapolis, Minnesota 55402

Attention: Seres Therapeutics Administrator

Telephone: (612) 217-5651

The Company or the Trustee by notice to the other may designate additional or different addresses for subsequent notices or communications.

Any notice or communication to a Securityholder shall be sent electronically or by first-class mail to his, her or its address shown on the register kept by the Registrar, in accordance with the procedures of the Depositary. Failure to send a notice or communication to a Securityholder of any Series or any defect in it shall not affect its sufficiency with respect to other Securityholders of that or any other Series.

If a notice or communication is sent or published in the manner provided above, within the time prescribed, it is duly given, whether or not the Securityholder receives it.

If the Company sends a notice or communication to Securityholders, it shall send a copy to the Trustee and each Agent at the same time.

 

40


© Seres Therapeutics. All Rights Reserved.